Breaking News

Lilly to Acquire Novartis Animal Health

April 22, 2014

Creates second-largest animal health company

Eli Lilly and Co. has entered an agreement to acquire Novartis Animal Health for approximately $5.4 billion in cash. The acquisition expands Lilly's animal health business, Elanco, and creates the second-largest animal health company in terms of global revenue.
 
Novartis Animal Health has a presence in 40 countries and had approximately $1.1 billion in revenues in 2013. Lilly will acquire its nine manufacturing sites, six dedicated R&D facilities, a global commercial infrastructure with a portfolio of approximately 600 products, a pipeline of more than 40 projects in development, and a team of more than 3,000 employees.
 
The transaction is expected to close by 1Q15, subject to customary closing conditions.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks